BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24832830)

  • 1. Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries.
    Gulácsi L
    Eur J Health Econ; 2014 May; 15 Suppl 1():S1-4. PubMed ID: 24832830
    [No Abstract]   [Full Text] [Related]  

  • 2. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
    Simoens S; Huys I
    Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?
    Fiorino G; Fazio M; Danese S
    Expert Rev Clin Immunol; 2016; 12(4):361-3. PubMed ID: 26752540
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biosimilars: assessment of efficacy, safety and cost].
    Domínguez-Gil Hurlé A
    Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Medicines Agency guidelines to increase the pace of biosimilar development.
    Parks L
    Bioanalysis; 2012 Nov; 4(22):2665. PubMed ID: 23346558
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilar medicines in inflammatory bowel disease.
    Moum B; Lundin KE
    Tidsskr Nor Laegeforen; 2014 Apr; 134(8):819-20. PubMed ID: 24780979
    [No Abstract]   [Full Text] [Related]  

  • 8. The European biosimilars market remains underdeveloped.
    Prescrire Int; 2015 Mar; 24(158):82. PubMed ID: 25897465
    [No Abstract]   [Full Text] [Related]  

  • 9. Biosimilar competition: lessons from Europe.
    Grabowski H; Guha R; Salgado M
    Nat Rev Drug Discov; 2014 Feb; 13(2):99-100. PubMed ID: 24445562
    [No Abstract]   [Full Text] [Related]  

  • 10. The rise of biosimilars in cancer care.
    Roe H
    Br J Nurs; 2015 Feb 26-Mar 11; 24(4):S28-9. PubMed ID: 25723369
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological and biosimilar drugs: Clarifying concepts].
    Rodriguez Cumplido D; Asensio Ostos C
    Aten Primaria; 2018; 50(6):323-324. PubMed ID: 29605234
    [No Abstract]   [Full Text] [Related]  

  • 13. Monoclonal antibody biosimilars.
    Udpa N; Million RP
    Nat Rev Drug Discov; 2016 Jan; 15(1):13-4. PubMed ID: 26678619
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosimilars: Reimbursement Issues in Your Oncology Practice.
    Conti RM
    J Oncol Pract; 2017 Sep; 13(9_suppl):12s-14s. PubMed ID: 28898590
    [No Abstract]   [Full Text] [Related]  

  • 15. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction and commentary: Paving the way for biosimilars in oncology.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
    [No Abstract]   [Full Text] [Related]  

  • 17. Biosimilars take center stage.
    Adams KT
    Manag Care; 2014 Apr; 23(4):44-6. PubMed ID: 24864533
    [No Abstract]   [Full Text] [Related]  

  • 18. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries.
    Kaló Z; Landa K; Doležal T; Vokó Z
    Eur J Cancer Care (Engl); 2012 Jul; 21(4):442-9. PubMed ID: 22510226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Policies in Central and Eastern European Countries.
    Janhz-Różyk K; Kawalec P; Szkultecka-Debek M
    Value Health Reg Issues; 2017 Sep; 13():59-60. PubMed ID: 29073990
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective pharmaceutical regulation needs alignment with doctors.
    Ebbers HC; Pieters T; Leufkens HG; Schellekens H
    Drug Discov Today; 2012 Feb; 17(3-4):100-3. PubMed ID: 22001600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.